Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DETERMINE: Targeted Therapies in Rare Cancers with Actionable Genomic Alterations
NCT05722886Phase 3Recruiting
- Sponsor
- Cancer Research UK
- Start
- Mar 2023
- Primary completion
- Oct 2029
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 3, open-label trial of alectinib, atezolizumab, entrectinib, trastuzumab, pertuzumab and 5 more in rare cancer, solid tumor and hematological malignancy (7 arms), sponsored by Cancer Research UK. Primary endpoint: Number of patients who consent to each arm at 5 years. Started Mar 2023; status: recruiting.
02
Drugs
03
Conditions
rare cancersolid tumorhematological malignancy
Beyond the preview
Go deeper on NCT05722886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05722886.